Buscar
Mostrando ítems 1-10 de 43
Histomorphometry of the postmenopausal endometrium after oral and transdermal estrogen replacement therapy
(Lippincott-raven Publ, 1996-03-01)
We studied the morphological and morphometrical aspects of the endometrium of postmenopausal women treated with oral conjugated estrogens and transdermal 17 beta-estradiol for 28 days. Light microscopy revealed that the ...
Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women
(Elsevier B.V., 1996-04-01)
An open-label, randomised, crossover study was conducted with in healthy postmenopausal women to compare the relative bioavailability of a matrix transdermal estradiol delivery system worn for 7 consecutive days, versus a ...
Carotid and uterine vascular resistance in short-term hormone replacement therapy postmenopausal users
(Elsevier Sci Ireland LtdClareIrlanda, 2004)
Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome
(Blackwell Publishing Ltd, 2018)
© 2018 John Wiley & Sons Ltd Objective: The established link between oestrogen and breast cancer occurs via both oestrogen receptor (ER)-mediated and non ER-mediated mechanisms. The term genotoxic estrogens describes ...
Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study
(I R O G CANADA, INCTORONTO, 2011)
Objective: To evaluate thromboelastographic parameters and fibrinogen levels in women treated with transdermal 17 beta estradiol. Methods: 29 menopausal women with a history of venous thromboembolic disease were included. ...
Sequential estrogen-progestin replacement therapy in healthy postmenopausal women: Effects on cholesterol efflux capacity and key proteins regulating high-density lipoprotein levels
(W B SAUNDERS CO-ELSEVIER INC, 2002)
Thirty healthy postmenopausal women were randomized into 2 groups that received a sequential combined hormone-replacement therapy (HRT) (n = 18; conjugated equine estrogen 0.625 mg/d for 28 days and 5 mg of medroxyprogesterone ...
¿Son los estrógenos transdérmicos cardioprotectores?
(Sociedad Médica de Santiago, 2001)
Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome
(John Wiley & Sons, 2019)
Objective: The established link between oestrogen and breast cancer occurs via both oestrogen receptor (ER)-mediated and non ER-mediated mechanisms. The term genotoxic estrogens describes mutagenic metabolites, including ...
Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women
(Munksgaard Int Publ Ltd, 1998-03-01)
Background. This study was performed to evaluate antithrombin III levels in postmenopausal women receiving hormonal replacement treatment.Methods. It is a prospective randomized study concerning 19 postmenopausal patients, ...
Hormone therapy in Brazilian postmenopausal women with chronic hepatitis C: a pilot study
(TAYLOR & FRANCIS LTD, 2010)
Design Fifty out of 336 postmenopausal patients with chronic infection with the hepatitis C virus were selected. The non-inclusion criteria were other chronic or systemic liver diseases, severe vascular diseases, autoimmune ...